第21回 札幌国際がんシンポジウム

テーマ

"Epstein-Barr Virus and Human Cancer"

日時

2001年7月4日~6日

会場

北海道大学 学術交流会館(札幌市北区)

代表世話人

高田 賢蔵 (北海道大学)

The 21st Sapporo International Cancer Symposium

Theme:

"Epstein-Barr Virus and Human Cancer"

Date:

July 4-6, 2001

Venue:

Hokkaido University Conference Hall, Sapporo, Japan

Organizers (*Chairperson)

Kenzo Takada*

Elliott Kieff

Bill Sugden

Program

Session 1. EBV-associated Malignancies

EBV and nasopharyngeal carcinoma

Dolly P. Huang (The Chinese University of Hong Kong, Hong Kong)

Molecular pathology of EBV-associated gastric carcinoma Masashi Fukayama (University of Tokyo)

EBV association with breast cancer

Irene Joab (Hospital Saint-Louis, France)

Characterization of EBV immune response in HD patients and characterization of serum viral load in patients destined to develop HD

Richard F. Ambinder (Johns Hopkins Comprehensive Cancer Center, USA)

EBV and nasal NK/T-cell lymphoma

Katsuyuki Aozasa (Osaka University, Japan)

Session 2. Molecular Mechanisms of Oncogenesis I

Molecular biology of EBV in cell lines and cancers

Paul Farrell (Imperial College, UK)

EB virus modulation of host cell function in latency and tumor risk

Ingemar Ernberg (Karolinska Institutet, Sweden)

Epstein-Barr virus nuclear protein I

Elliott Kieff (Harvard University, USA)

Overexpression of c-myc imposes a non-immunogenic phenotype on Epstein-Barr virus-infected human B cells

Georg W. Bornkamm (GSF Research Center, Germany)

EBER as an oncogenic RNA molecule

Kenzo Takada (Hokkaido University, Japan)

BARF1 gene as a viral oncogene

Tadamasa Ooka (University Claude Bernard Lyon-1, France)

Signaling by the latent membrane protein 1 of Epstein-Barr virus Bill Sugden (University of Wisconsin-Madison, USA)

Cellular targets of LMP1 signaling

Wolfgang Hammerschmidt (Ludwig-Maximillians-University, Germany)

Session 3. Molecular Mechanisms of Oncogenesis II

The impact of EBV latent gene expression on the epithelial cell phenotype Lawrence S. Young (University of Birmingham, USA)

LMP1 transgenic mice: Identification of activated signaling pathways and synergy with p16 deletion or carcinogen treatment

Nancy Raab-Traub (University of North Carolina, USA)

LMP2 function in EBV latency

Richard Longnecker (Lurie Comprehensive Cancer Center, USA)

The importance of envelope proteins

Lindsey Hutt-Fretcher (University of Missouri-Kansas City, USA)

Does protein kinase C play an obligatory role in activation of the EBV lytic cascade? George Miller (Yale University, USA)

EBV DNA replication proteins

Tatsuya Tsurumi (Aichi Cancer Center, Japan)

Special Lectures

Reflections on Epstein-Barr virus: From palaovirology to molecular biology Anthony Epstein (University of Oxford, UK)

Infections and cancer – The end of a long story?

Harald zur Hausen (Deutsches Krebsforschungszentrum, Heidelberg, Germany)

Session 4. Animal Model and Therapeutic Approaches to Malignancy

Non-human lymphocryptoviruses: models for studying EBV pathogenesis Fred Wang (Harvard Medical School, USA)

Therapeutic opportunities for controlling EBV-associated diseases Denis Moss (University of Queensland, UK)

EBV-specific CTLs to treat EBV-associated tumors Cliona M. Rooney (Baylor College of Medicine, USA)